Director, Medical Affairs – Oncology & Hematology

Ipsen Biopharmaceuticals Inc.; Cambridge (MA); On-site; USD 225,000 - 300,000; Full time

Benefits offered by this job

401(k) with company contributions

Health, dental & vision coverage

Parental leave

Discretionary winter shutdown

Job summary

Ipsen Biopharmaceuticals, Inc. in the United States seeks a Director, Medical Affairs (Oncology) to lead medical strategy for the US myelofibrosis portfolio, oversee advisory boards, and ensure scientific accuracy across promotional and non-promotional materials.

The role partners with US Medical Affairs, Clinical Operations, and field teams to guide education, manage budgets, and advance clinical programs while traveling up to 40% to engage thought leaders and assess investigator-sponsored

Qualifications

• 8+ years of experience in the pharmaceutical industry with strong oncology focus.
• Proven ability to lead medical affairs strategy and cross-functional collaboration.
• Knowledge of clinical trial design, biostatistics, and regulatory guidelines.

Responsibilities

• Lead US medical strategy for the oncology portfolio, focused on myelofibrosis and potential AML.
• Oversee medical review of promotional and non-promotional content and medical information responses.
• Develop and monitor medical plans, advisory boards, and field medical strategy with cross-functional teams.
• Manage budgets for independent educational grants and oversee scientific communications.

Skills

Oncology experience

Medical Affairs strategy

Clinical trial design

Regulatory knowledge

Leadership

Education

Advanced degree in a scientific discipline

Job description

Ipsen Biopharmaceuticals, Inc. in the United States seeks a Director, Medical Affairs (Oncology) to lead medical strategy for the US myelofibrosis portfolio, oversee advisory boards, and ensure scientific accuracy across promotional and non-promotional materials.

The role partners with US Medical Affairs, Clinical Operations, and field teams to guide education, manage budgets, and advance clinical programs while traveling up to 40% to engage thought leaders and assess investigator-sponsored